|
|
|
|
|
|
Pharmaceutical Pricing and Reimbursement of Established Drugs
Pharmaceutical Pricing and Reimbursement Market Strategies
Business Insights
The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing. Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies. By incorporating such assessments into portfolio evaluations and lifecycle planning, companies can enhance their understanding of potential price profiles for individual drugs and optimise future returns.
‘Pharmaceutical Pricing and Reimbursement’ is a report that examines the tactical importance of price optimization throughout the product lifecycle. The key issues affecting pricing and reimbursement disciplines are identified and the market environments of individual countries are assessed. This report will also detail the global and lifecycle pricing strategies of established drugs, including actionable recommendations and detailed case studies, and provide forecasts for future pricing scenarios in major markets.
Published: Nov 2007
143 pages
Publication Date : November 2007
|
|
|
|
|
|
|
Strategic Alliances in World Pharma and Biotech Markets
In the last decade or so, strategic alliances and partnerships among pharmaceutical and biotech companies have doubled to around 700 per year per sector, although most of this increase came in the early years.
Regardless of its size, every pharma or biotech company has certain limitations in their own research although usually they have enough capacity in development to bring new compounds to the market very effectively.
However, on a number of occasions, the inhouse development capacity may get prioritized in favor of other products within the company’s portfolio.
A product may also be facing competition internally from other projects, not necessarily similar compounds, but perhaps programs better aligned to the overall R&D activities. (MORE)
|
|
|
|
|
|
|
|
|
|
|
)